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INTRODUCTION
Pathological neovascularization plays a key role in the patho-
physiology of various diseases including cancers, heart diseas-
es, and ocular diseases. In the eye, pathological neovasculariza-
tion is associated with leading causes of blindness in all age 
groups; retinopathy of prematurity in children, diabetic retinop-
athy in adults, and age-related macular degeneration (AMD) in 
the elderly.1 Blocking neovascularization using vascular endo-
thelial growth factor (VEGF) inhibitors has been successfully 
employed in the clinic to treat these sight-threatening diseas-
es,2-5 but anti-VEGF therapies are still ineffective in significant 
number of patients, especially in AMD patients. 
A master regulator of the hypoxic response is the hypoxia-
inducible factor (HIF)-1, a heterodimeric transcription factor 
composed of an α-subunit whose proteasomal degradation is 
tightly regulated by oxygen tension and constitutively ex-
pressed β-subunit.6 Under hypoxic conditions, the HIF-1 com-
plex binds hypoxia response elements at promoters and en-
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hancers of target genes, and induces expression of a wide array 
of pro-angiogenic molecules including VEGF, platelet-derived 
growth factor (PDGF), and basic fibroblast growth factor 
(bFGF).7 Because the HIF pathway is a master regulator of an-
giogenesis, and modulates multiple pro-angiogenic pathways, 
it represents an attractive target for anti-angiogenic therapy. 
Furthermore, HIF-1 has been found to be expressed in human 
choroidal neovascularization (CNV) membrane, which is a 
pathognomonic feature of neovascular type AMD, and retinal 
pigment epithelial (RPE) cells.8,9 
Resveratrol (trans-3,4,5’-trihydroxystibene), a naturally oc-
curring polyphenolic compound found in grapes and red 
wine, has received a great deal of attention due to its beneficial 
roles involving anti-oxidant, anti-inflammatory, anti-aging, and 
anti-carcinogenic activities.10,11 Studies have also shown that 
resveratrol potently suppresses VEGF in various cancer cells, 
possibly via inhibition of HIF-1α.12-14 In the present study, we 
demonstrated that resveratrol can inhibit expression and se-
cretion of VEGF by inhibition of HIF-1α in human RPE cells 
under hypoxic conditions. The inhibitory effects of orally ad-
ministered resveratrol on laser-induced CNV in a mouse mod-
el were also investigated. 
MATERIALS AND METHODS 
Regents 
Resveratrol was purchased from Sigma-Aldrich (St. Louis, MO, 
USA). LY294002, PD98059, and SB203528 were purchased from 
Calbiochem (San Diego, CA, USA). The protein synthesis in-
hibitor, cycloheximide, and the proteasome inhibitor, MG132 
(Z-leu-leu-CHO), were purchased from Calbiochem (Darm-
stadt, Germany). Primary antibody to HIF-1α was purchased 
from BD Transduction Laboratories (San Diego, CA, USA). An-
tibodies to phosphorylated Akt1/2/3 (Ser437) and total Akt 1/2 
(N-19) were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA). Primary antibodies to phosphorylated mTOR 
(Ser2448) and total mTOR were purchased from Cell Signaling 
Technology (Beverly, MA, USA). Rapamycin and everilomus 
were purchased from Sigma-Aldrich.
Cell culture 
Human retinal pigment epithelial cells (ARPE-19) were pur-
chased from ATCC (Manassas, VA, USA). Cells were cultured in 
Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 
(DMEM/F12) medium (Invitrogen, Carlsbad, CA, USA), sup-
plemented with 10% fetal bovine serum, penicillin (100 units/
mL), and streptomycin (100 μg/mL).
Hypoxia culture conditions
Cells were cultured to –80% confluency, and then transferred to 
hypoxic conditions, using a modulator incubator chamber (Bil-
lups-Rothenberg, Del Mar, CA, USA), which was flushed for 10 
minutes with a gas mixture containing 95% N2/5% CO2, result-
ing in a final concentration of 3% O2. The incubator chambers 
were sealed and placed in a traditional incubator at 37°C.
Resveratrol treatment of ARPE-19 cells
ARPE-19 cells, 70–80% confluent in complete medium, were 
pretreated for 1 hour with different concentrations of resvera-
trol (10 μmol/L, 50 μmol/L, and 100 μmol/L), followed by incu-
bation under hypoxic conditions for 4 or 16 hours. To deter-
mine the effects of resveratrol on the half-life or degradation of 
hypoxia-induced HIF-1α protein, ARPE-19 cells were pretreat-
ed for 1 hour with 10 μg/mL cycloheximide or 20 μmol/L of 
MG132 and cultured in the presence or absence of 100 μmol/L 
resveratrol for 6 hours under hypoxic conditions.
RT-PCR analysis of HIF-1α and VEGF mRNA levels in 
ARPE-19 cells
Total RNA was isolated from ARPE-19 cells using Ribospin (Ge-
neAll, Inc., Seoul, Korea). Reverse transcription-polymerase 
chain reaction (RT-PCR) analysis of VEGF and glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) mRNA levels were de-
termined using the M-MLV kit (Invitrogen) with primers specif-
ic for HIF-1α (forward primer, 5’-TCACCACAGGACAGTACAG 
GATGC-3’and reverse primer, 5’-CCAGCAAAGTTAAAGCAT 
CAGGTTCC-3’); for human VEGF (forward primer, 5’-ACG 
AAGTGGTGAAGTTCATGGATG-3’ and reverse primer, 5’-TTC 
TGTATCAGTCTTTCCTGGTGAG-3’); and for human GAPDH 
(forward primer, 5’-GCCAAAGGGTCATCATCTC-3’ and re-
verse primer, 5’-GTAGAGGCAGGGATGATGTT-3’). All the 
primers were synthesized by Genolution (Genolution, Seoul, 
Korea).
Western blot analysis
Cells were washed once with cold phosphate-buffered saline 
(PBS), solubilized with lysis buffer [40 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES) (pH 7.5), 120 mM 
NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 1% Tri-
ton X-100, and 1 tablet of EDTA free protease inhibitor cocktail 
(Roche, Indianapolis, IN, USA)]. The lysed samples were centri-
fuged at 20817×g (14000 rpm) for 1 hour at 4°C to obtain the su-
pernatant. Total protein in the supernatant was quantified us-
ing the bicinchoninic acid (BCA) protein assay kit (Thermo 
Fisher Scientific, Waltham, MA, USA) using bovine serum albu-
min as a standard. The proteins were blotted onto polyvinyli-
dene difluoride (PVDF) membranes (Millipore Co., Bedford, 
MA, USA) after separation by 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). The mem-
branes were blocked for 1 hour with 10% non-fat dry milk (No-
ble Bio, Hwaseong, Korea) in Tris-buffered saline containing 
0.1% Tween-20 (TBS-T), and incubated overnight with primary 
antibody at 4°C. The membranes were then washed 4 times 
with TBS-T for 10 minutes each at room temperature, and incu-
bated with horseradish peroxidase-conjugated secondary anti-
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body for 1 hour. The blots were developed using the ECL che-
miluminescence reagent kit (Santa Cruz Biotechnology and 
Millipore).
Cell viability assay 
ARPE-19 cells were plated onto 48-well plates at 2.5×105 cells 
per well. After pretreatment with different concentrations of 
resveratrol for 1 hour, cells were placed under hypoxic condi-
tions for 16 hours. Viable cells were determined using the MTT 
assay and the In Vitro Toxicology Assay Kit, Neutral Red based 
(Sigma-Aldrich), according to the manufacturer’s instructions.
VEGF Enzyme-Linked Immunosorbent Assay (ELISA)
To determine VEGF secretion by ARPE-19 cells under hypoxic 
conditions, culture medium was assayed for VEGF using the 
Quantikine human VEGF immunoassay (Koma Biotech, Inc., 
Seoul, Korea), according to the manufacturer’s instructions. 
In vitro treatment of human mTOR with siRNA
ARPE-19 cells were seeded into 100-mm cell culture dishes, 
transfected with either siRNA for the human mTOR gene, or 
with randomly scrambled siRNA (both synthesized by Geno-
lution), using Lipofectamine RNAiMAX (Invitrogen) according 
to the manufacturer’s instructions. The human mTOR siRNA 
contained specific target sequences (sense, 5’-CCCUGCCUU 
UGUCAUGCCUUU-3’ and antisense, 5’-AGGCAUGACAAAG 
GCAGGGUU-3’), and the scrambled siRNA contained the se-
quences (sense, 5’-ACGUGACACGUUCGGAGAAUU-3’ and 
antisense 5’-UUCUCCGAACGUGUCACGUUU-3’). The cells 
were transfected with an additional 20 nM/100 mm dish of 
mTOR siRNA or scrambled siRNA for 4 hours, followed by a 
change of medium and incubation for 48 hours, and then in-
cubated under hypoxic conditions for 16 hours. The effects of 
siRNA treatment were determined using western blot analysis, 
luciferase assays, and RT-PCR. 
Animal model of CNV
All mice were handled in accordance with the Association for 
Research in Vision and Ophthalmology Statement for the Use 
of Animals in Ophthalmic and Vision Research. Protocols were 
approved by the Institutional Animal Care and Use Committee 
of Yonsei University, Seoul, Korea. CNV was induced by laser 
photocoagulation as previously described.15 Briefly, nine-week-
old male C57BL/6 mice were anesthetized with intraperitoneal 
tiletamine-zolazepam (30 mg/kg, Zoletil; Virbac, Carros, France) 
and xylazine (10 mg/kg; Rompun, Bayer Korea Ltd., Seoul, Ko-
rea). Mice pupils were dilated with 0.5% tropicamide and 0.5% 
phenylephrine (Mydrin-P; Santen Pharmaceutical Co., Osaka, 
Japan). Argon green laser photocoagulation (100 μm spot size, 
180 mW power, and 0.1 second duration, Ultima 2000 SE, Lu-
menis, Santa Clara, CA, USA) was performed with a slit lamp 
delivery system. Three to four laser burns were made in each eye 
at the 3, 6, 9, and 12 o’clock positions, approximately 2 disc di-
ameters from the optic nerve. Only laser burns that produced a 
cavitation bubble, which indicates the rupture of Bruch’s mem-
brane, were included in the study. 
Resveratrol assay
Resveratrol is a white solid powder, soluble in 10% ethanol/90% 
H2O at room temperature. 
The resveratrol solution was thawed immediately prior to 
oral administration. The mice were randomized into three 
groups: 1) a control group with vehicle only (10% ethanol/90% 
H2O), 2) a low dose group with 1 mg/kg/day resveratrol, and 3) a 
high dose group with 10 mg/kg/day resveratrol. Each drug was 
administered one day after laser photocoagulation and daily 
given once thereafter. 
Choroidal flat mounts
After 7 days of oral administration of drugs, 24 eyes (8 eyes from 
4 mice per group) were subjected to choroidal flat mounts. The 
eyes were enucleated and immediately fixed in 4% paraformal-
dehyde in PBS for 1 hour. Under a stereoscopic microscope, the 
anterior segments were removed, and the neurosensory retinas 
were detached and separated from the optic nerve head. After 4 
radial incisions, the eyecups were washed with cold PBlec solu-
tion [0.1 mM CaCl2, 0.1 mM MgCl2, 0.1 mM MnCl2, and 1% Tri-
ton X-100 in PBS (pH 6.8)] by overnight incubation at 4°C. The 
eyecups were incubated overnight with a 1:1000 dilution of a 10 
mg/mL solution of 4’,6-diamidino-2-phenylindole (DAPI), and 
a 1:100 dilution of a 1 mg/mL solution of isolectin IB4 conjugat-
ed with Alexa Fluor 488 (Invitrogen-Molecular Probes, Eugene, 
OR, USA) in a cold chamber at 4°C, followed by washing with 
cold PBS and then flat-mounted with the RPE side facing up.16,17 
The samples were covered and sealed for confocal microscopic 
analysis (LSM 700META, Carl Zeiss, Thornwood, NY, USA) at 
488 nm (FITC) and at 405 nm (DAPI).
Statistical analysis 
All statistical parameters were calculated using GraphPad 
Prism 5.0 software. The results were analyzed by one-way anal-
ysis of variance. The size of the CNV lesions was evaluated by 
ANOVA, followed by the Dunnett’s post hoc test. Differences 
with a p-value less than 0.05 were considered statistically signif-
icant.
RESULTS
Effects of resveratrol on CNV lesion size
Resveratrol treatment via oral feeding for 1 week did not induce 
any significant side effects, including weight loss, infection, and 
death. The recipient mice maintained normal appetite and ac-
tivity. However, resveratrol treatment resulted in a significant 
reduction in the area of laser-induced CNV on day 7. An image 
analysis of CNV on choroidal flat mounts showed that the median 
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(mean±SD) CNV areas of the vehicle group, low dose group (1 
mg/kg), and high dose group (10 mg/kg) were 21607 (29730± 
12940) μm2, 13432 (17184±10835) μm2, and 9005 (12186±6320) 
μm2, respectively. There was 37.8% (42.2%, for the mean value) 
decrease in the median CNV size in the low dose group, and 
58.3% (59.0%, for the mean value) decrease in the high dose 
group, compared to the vehicle group. The differences were 
statistically significant for both low dose (p<0.001) and high 
dose groups (p<0.001) (Fig. 1).
Resveratrol inhibited HIF-1α and VEGF via the PI3K/
Akt/mTOR signaling pathway
To determine whether resveratrol could inhibit VEGF expres-
sion in human ARPE-19 cells under hypoxic conditions, we 
determined VEGF mRNA expression by using RT-PCR, and the 
level of VEGF secretion using by ELISA. The results showed that 
treatment of ARPE-19 cells with resveratrol resulted in a dose-
dependent decrease of VEGF expression at both mRNA and 
protein levels (Fig. 2A and B). The cell viability assays indicated 
that the decrease of VEGF expression by resveratrol was not 
due to cell death. 
Pretreatment of ARPE-19 cells with resveratrol abrogated the 
hypoxia-induced HIF-1α protein accumulation in a dose-de-
pendent manner (Fig. 2C). HIF-1α expression and its down-
stream target gene expressions have been found to be regulat-
ed by major signal transduction pathways, including PI3K/Akt 
and ERK/MAPK.18,19 To determine whether these pathways 
were involved, ARPE-19 cells were pretreated with specific in-
hibitors of PI3K (50 μM LY294002), ERK1/2 (50 μM PD98059), 
and p38 MAPK (20 μM SB203528) for 1 hour, followed by in-
cubation under hypoxic conditions. Pretreatment of ARPE-19 
cells with LY294002 suppressed HIF-1α protein accumulation 
and VEGF mRNA expression, suggesting the involvement of 
PI3K/Akt activation in HIF-1α expression and its downstream 
VEGF gene expression in ARPE-19 cells (data not shown). To 
determine whether resveratrol inhibited hypoxia-mediated 
Akt phosphorylation and its downstream mammalian target of 
mTOR phosphorylation, ARPE-19 cells were pretreated with 
varying concentrations of resveratrol for 1 hour, followed by 
hypoxic incubation for 6 hours, and then the levels of phos-
pho-Akt and phospho-mTOR were analyzed using western 
blots. The results showed that pretreatment with resveratrol 
Fig. 1. Resveratrol inhibited choroidal neovascularization (CNV) growth in animal model. Effects of orally-administered resveratrol on lesion size in la-
ser-induced CNV mice at Bruch membrane rupture sites. Representative photographs of choroidal flat mounts 7 days after laser photocoagulation 
are shown: (A) control group, (B) low dose group (1 mg/kg/day), and (C) high dose group (10 mg/kg/day). (D) Image analysis shows reduced CNV size 
from the resveratrol-treated mice. *p<0.001 and †p<0.0001 vs. the vehicle-treated control.
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cumulation mainly by promoting its stability, instead of in-
creasing its synthesis.21 To test whether resveratrol can inhibit 
hypoxia-induced HIF-1α protein accumulation by promoting 
its degradation, ARPE-19 cells were exposed to hypoxia for 4 
hours, followed by treatment with cycloheximide to block on-
going protein synthesis in the presence or absence of resvera-
trol for various time periods. Hypoxia-induced HIF-1α protein 
accumulation gradually decreased to an undetectable level at 
120 minutes following exposure to cycloheximide, whereas in 
the absence of resveratrol, HIF-1α protein levels remained rela-
tively stable (Fig. 4A and B). To further test whether the degra-
dation of hypoxia-induced HIF-1α protein promoted by resve-
ratrol was mediated by ubiquitination and 26S proteasome-
mediated degradation, ARPE-19 cells were treated with 26S 
proteasome inhibitor MG132 (20 μM) for 1 hour in the absence 
or presence of resveratrol. Inhibition of HIF-1α protein expres-
sion by resveratrol was significantly blocked in the presence of 
MG132, suggesting that the degradation of hypoxia-induced 
HIF-1α protein mediated by resveratrol was dependent on the 
proteasome degradation pathway in ARPE-19 cells (Fig. 4C). 
resulted in a dose-dependent decrease of both phospho-Akt 
and phospho-mTOR levels (Fig. 2D).
The mTOR molecule is one of the downstream targets of 
PI3K/Akt, which regulates signaling proteins which are impor-
tant for protein synthesis, such as p70S6 kinase.20 ARPE-19 cells 
were pretreated with mTOR inhibitors, rapamycin and everoli-
mus, followed by incubation under hypoxic conditions. As 
shown in Fig. 3A, these treatments resulted in a decrease in hy-
poxia-induced HIF-1α accumulation, along with abrogation of 
phospho-p70S6 kinase levels, the downstream target of mTOR 
(Fig. 3A). As a complementary strategy, we attempted to silence 
the mTOR gene using siRNA. Transfection of ARPE-19 cells 
with an mTOR siRNA effectively reduced hypoxia-induced 
HIF-1α protein accumulation, mTOR levels, phospho-mTOR 
protein levels, and phospho-p70S6 kinase levels (Fig. 3B). Si-
lencing of mTOR using siRNA also resulted in inhibition of hy-
poxia-induced VEGF secretion (Fig. 3C). 
Resveratrol inhibited HIF-1α accumulation by  
promoting protein degradation
HIF-1α protein levels are regulated by a balance between its 
synthesis and degradation. Hypoxia induces HIF-1α protein ac-
Fig. 2. Resveratrol inhibited hypoxia-inducible factor (HIF)-1α and vascular endothelial growth factor (VEGF) via the PI3K/Akt pathway. ARPE-19 cells 
in complete medium were pretreated with 10 μmol/L, 50 μmol/L, and 100 μmol/L resveratrol for 1 hour, and then exposed to normoxia or hypoxia for 16 
hours. Resveratrol significantly reduced VEGF protein and mRNA levels as determined by ELISA (A) and RT-PCR (B) in a dose-dependent manner. (C) 
Pretreatment with resveratrol in varying concentration abrogated the hypoxia-induced HIF-1α protein accumulation in a dose-dependent manner. (D) 
Pretreatment with resveratrol resulted in decrease of phospho-Akt (p-Akt) and phospho-mTOR (p-mTOR) levels in a dose-dependent manner. 
*p<0.0001 vs. the normoxia group, †p<0.001 vs. the hypoxia group. ELISA, Enzyme-Linked Immunosorbent Assay.
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DISCUSSION 
Resveratrol is a naturally occurring compound that has been of 
great interest because of its beneficial effects, including anti-
aging, anti-obesity, anti-inflammatory, and anti-carcinogenic 
activities.10,12,22 The effect of resveratrol on angiogenesis is com-
Fig. 3. (A) Inhibition of the mTOR pathway using rapamycin and everolimus prevented HIF-1α induction under hypoxic conditions in ARPE-19 cells as 
determined by immunoblotting of HIF-1α and p-p70S6 kinase. (B) Transfection of ARPE-19 cells with human mTOR siRNA resulted in HIF-1α, phospho-
mTOR, mTOR, and phospho-p70S6 kinase as determined by western blot. (C) Silencing of mTOR using siRNA resulted in inhibition of hypoxia-induced 
vascular endothelial growth factor (VEGF) in ARPE-19 cells. *p<0.0001 vs. the control group. HIF, hypoxia-inducible factor; p-mTOR, phospho-mTOR.
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μmol/L of resveratrol (RSV), for different time periods, and then analyzed by western blotting for HIF-1α protein. Hypoxia-induced HIF-1α protein accu-
mulation gradually decreased to an undetectable level at 120 minutes in the presence of resveratrol (B). (C) Inhibition of hypoxia-induced HIF-1α pro-
tein accumulation by resveratrol was significantly blocked in the presence of MG132, a 26S proteasome inhibitor. HIF, hypoxia-inducible factor.
A
HIF-1α
β-actin
Hypoxia –
–
–
+
0
–
+ + + +
30
–
60
–
120
–
180
–
+
15
–
CHX (min)
RSV
C
HIF-1α
β-actin
MG132 (20 μM) –
–
–
–
+ +
+ –
–
+RSV (100 μM)
B
HIF-1α
β-actin
Hypoxia –
–
–
+
0
+
+ + + +
30
+
60
+
120
+
180
+
+
15
+
CHX (min)
RSV
http://dx.doi.org/10.3349/ymj.2015.56.6.16781684
Resveratrol Inhibits Pathological Neovascularization
plex; it has been shown to be pro-angiogenic in the ischemic 
myocardium, but anti-angiogenic in cancer cells.12,13,23 In the 
eye, resveratrol has been shown to inhibit proliferation of hy-
poxic choroidal vascular endothelial cells.24 We found that res-
veratrol inhibited VEGF secretion via an HIF-1 dependent 
pathway in human RPE cells, and inhibited CNV growth in la-
ser-induced CNV mice. 
In ARPE-19 cells, HIF-1α protein expression under hypoxia 
was found to be dependent on the PI3K/Akt/mTOR pathway. 
HIF-1α protein level is also tightly regulated by oxygen tension 
via ubiquitination and 26S proteasomal degradation system.25 
Under hypoxic conditions, degradation of HIF-1α protein via 
ubiquitination is inhibited, leading to stabilization and accu-
mulation of HIF-1α protein. We found that resveratrol short-
ened the half-life of hypoxia-induced HIF-1α protein (Fig. 4A 
and B). This effect was significantly reduced in the presence of 
MG132, a 26S proteasome inhibitor (Fig. 4C). These results are 
consistent with previous studies of cancer cells,12,13 suggesting 
that resveratrol inhibits HIF-1α protein levels by regulating both 
protein translation and protein degradation. This dual effect 
may explain why there was still a mild inhibition of HIF-1α ac-
cumulation by resveratrol in the presence of MG132 (Fig. 4C). 
Although HIF-1α degradation by resveratrol was blocked, inhi-
bition of HIF-1α translation by resveratrol can still be possible 
via PI3K/Akt/mTOR pathway. 
The laser injury-induced mouse CNV model has been wide-
ly used for studying neovascular AMD.26 In this animal model, 
oral administration of resveratrol markedly inhibited CNV pro-
gression in a dose-dependent manner. Analyses of choroidal 
flat mounts demonstrated a mean 42.2% reduction of CNV ar-
eas in the low dose group, and a mean 59.0% reduction in the 
high dose group (Fig. 1). Consistent with these results, a previ-
ous studies found a significant reduction in laser-induced 
mouse CNV using systemic administration of resveratrol or 
grape power via implanted osmotic pumps or oral gavage.27,28 
However, in the above studies, administration of resveratrol or 
grape power began 5 to 7 days before laser-induced injury and 
continued after CNV induction. In the present study, however, 
oral administration of resveratrol began one day after laser in-
duced injury and continued for 7 days thereafter, nevertheless, 
significant CNV suppression was achieved, further providing 
evidence for its therapeutic potential in the management of 
CNV. Prolonged pre-treatment with resveratrol could have re-
sulted in improved anti-angiogenic response. The anti-angio-
genic effect of resveratrol has been found in other pathological 
angiogenesis models of ocular disease, as well. Resveratrol in-
hibited retinal neovascularization in very low-density lipopro-
tein receptor knock-out mice and diabetes-induced early vas-
cular lesions in mouse retina.29,30 
In summary, our study has provided both in vitro and in vivo 
evidence that resveratrol exerts anti-angiogenic effects on CNV 
through its potent inhibition of HIF-1α via PI3K/Akt/mTOR path-
way. This finding suggests a therapeutic value of resveratrol in 
AMD patients, possibly as an adjunct oral therapy to current in-
travitreal anti-VEGF treatments. The anti-angiogenic properties 
of resveratrol might also be exploited to treat various ocular dis-
orders and other diseases that involve abnormal angiogenesis. 
ACKNOWLEDGEMENTS
The authors wish to thank Dr. Jeong Hun Kim and Dr. Dong 
Hyun Jo [Fight against Angiogenesis-Related Blindness (FARB) 
laboratory], Seoul National University College of Medicine, 
Seoul, Korea for kind support in establishing a laser CNV mouse 
model. This study was supported by a grant of the Korean Health 
Technology R&D Project, Ministry for Health, Welfare & Family 
Affairs, Republic of Korea (A110272), and a faculty research grant 
of Yonsei University College of Medicine for 2011 (6-2011-0068).
REFERENCES
1. Hyman LG, Lilienfeld AM, Ferris FL 3rd, Fine SL. Senile macular 
degeneration: a case-control study. Am J Epidemiol 1983;118:213-
27.
2. Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooper-
ative Group. Efficacy of intravitreal bevacizumab for stage 3+ reti-
nopathy of prematurity. N Engl J Med 2011;364:603-15.
3. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, 
et al. Ranibizumab versus verteporfin for neovascular age-related 
macular degeneration. N Engl J Med 2006;355:1432-44.
4. Lux A, Llacer H, Heussen FM, Joussen AM. Non-responders to 
bevacizumab (Avastin) therapy of choroidal neovascular lesions. 
Br J Ophthalmol 2007;91:1318-22. 
5. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen 
M, et al. Safety and efficacy of ranibizumab in diabetic macular 
edema (RESOLVE Study): a 12-month, randomized, controlled, 
double-masked, multicenter phase II study. Diabetes Care 2010; 
33:2399-405. 
6. Semenza GL. Expression of hypoxia-inducible factor 1: mecha-
nisms and consequences. Biochem Pharmacol 2000;59:47-53.
7. Semenza GL. HIF-1: mediator of physiological and pathophysio-
logical responses to hypoxia. J Appl Physiol (1985) 2000;88:1474-
80.
8. Inoue Y, Yanagi Y, Matsuura K, Takahashi H, Tamaki Y, Araie M. 
Expression of hypoxia-inducible factor 1alpha and 2alpha in cho-
roidal neovascular membranes associated with age-related mac-
ular degeneration. Br J Ophthalmol 2007;91:1720-1.
9. Sheridan CM, Pate S, Hiscott P, Wong D, Pattwell DM, Kent D. Ex-
pression of hypoxia-inducible factor-1alpha and -2alpha in hu-
man choroidal neovascular membranes. Graefes Arch Clin Exp 
Ophthalmol 2009;247:1361-7.
10. Juhasz B, Varga B, Gesztelyi R, Kemeny-Beke A, Zsuga J, Tosaki A. 
Resveratrol: a multifunctional cytoprotective molecule. Curr Pharm 
Biotechnol 2010;11:810-8.
11. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, 
et al. Cancer chemopreventive activity of resveratrol, a natural 
product derived from grapes. Science 1997;275:218-20.
12. Zhang Q, Tang X, Lu QY, Zhang ZF, Brown J, Le AD. Resveratrol 
inhibits hypoxia-induced accumulation of hypoxia-inducible fac-
tor-1alpha and VEGF expression in human tongue squamous cell 
carcinoma and hepatoma cells. Mol Cancer Ther 2005;4:1465-74.
13. Cao Z, Fang J, Xia C, Shi X, Jiang BH. trans-3,4,5’-Trihydroxystibene 
1685http://dx.doi.org/10.3349/ymj.2015.56.6.1678
Christopher Seungkyu Lee, et al.
inhibits hypoxia-inducible factor 1alpha and vascular endothelial 
growth factor expression in human ovarian cancer cells. Clin Can-
cer Res 2004;10:5253-63.
14. Park SY, Jeong KJ, Lee J, Yoon DS, Choi WS, Kim YK, et al. Hypoxia 
enhances LPA-induced HIF-1alpha and VEGF expression: their 
inhibition by resveratrol. Cancer Lett 2007;258:63-9. 
15. Chung EJ, Yoo S, Lim HJ, Byeon SH, Lee JH, Koh HJ. Inhibition of 
choroidal neovascularisation in mice by systemic administration 
of the multikinase inhibitor, sorafenib. Br J Ophthalmol 2009;93: 
958-63.
16. Kang S, Roh YJ, Kim IB. Antiangiogenic effects of tivozanib, an oral 
VEGF receptor tyrosine kinase inhibitor, on experimental choroi-
dal neovascularization in mice. Exp Eye Res 2013;112:125-33.
17. Kang S, Park KC, Yang KJ, Choi HS, Kim SH, Roh YJ. Effect of cedi-
ranib, an inhibitor of vascular endothelial growth factor receptor 
tyrosine kinase, in a mouse model of choroidal neovasculariza-
tion. Clin Experiment Ophthalmol 2013;41:63-72. 
18. Semenza G. Signal transduction to hypoxia-inducible factor 1. 
Biochem Pharmacol 2002;64:993-8.
19. Minet E, Michel G, Mottet D, Raes M, Michiels C. Transduction 
pathways involved in Hypoxia-Inducible Factor-1 phosphoryla-
tion and activation. Free Radic Biol Med 2001;31:847-55.
20. Jiang H, Shang X, Wu H, Gautam SC, Al-Holou S, Li C, et al. Res-
veratrol downregulates PI3K/Akt/mTOR signaling pathways in 
human U251 glioma cells. J Exp Ther Oncol 2009;8:25-33.
21. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 
2003;3:721-32.
22. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. 
Resveratrol improves health and survival of mice on a high-calorie 
diet. Nature 2006;444:337-42. 
23. Kaga S, Zhan L, Matsumoto M, Maulik N. Resveratrol enhances 
neovascularization in the infarcted rat myocardium through the 
induction of thioredoxin-1, heme oxygenase-1 and vascular endo-
thelial growth factor. J Mol Cell Cardiol 2005;39:813-22. 
24. Balaiya S, Murthy RK, Chalam KV. Resveratrol inhibits prolifera-
tion of hypoxic choroidal vascular endothelial cells. Mol Vis 2013; 
19:2385-92.
25. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-induc-
ible factor 1alpha is mediated by an O2-dependent degradation 
domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci 
U S A 1998;95:7987-92.
26. Stahl A, Connor KM, Sapieha P, Chen J, Dennison RJ, Krah NM, et 
al. The mouse retina as an angiogenesis model. Invest Ophthal-
mol Vis Sci 2010;51:2813-26. 
27. Khan AA, Dace DS, Ryazanov AG, Kelly J, Apte RS. Resveratrol 
regulates pathologic angiogenesis by a eukaryotic elongation fac-
tor-2 kinase-regulated pathway. Am J Pathol 2010;177:481-92.
28. Kanavi MR, Darjatmoko S, Wang S, Azari AA, Farnoodian M, Ke-
nealey JD, et al. The sustained delivery of resveratrol or a defined 
grape powder inhibits new blood vessel formation in a mouse 
model of choroidal neovascularization. Molecules 2014;19:17578-
603.
29. Kim YH, Kim YS, Roh GS, Choi WS, Cho GJ. Resveratrol blocks di-
abetes-induced early vascular lesions and vascular endothelial 
growth factor induction in mouse retinas. Acta Ophthalmol 2012; 
90:e31-7. 
30. Hua J, Guerin KI, Chen J, Michán S, Stahl A, Krah NM, et al. Res-
veratrol inhibits pathologic retinal neovascularization in Vld-
lr(-/-) mice. Invest Ophthalmol Vis Sci 2011;52:2809-16.
